Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SDHDS: Spironolactone in Resistant Hypertension with Type 2 Diabetes
NCT01062763Phase 3Completed
- Start
- Mar 2010
- Primary completion
- Mar 2012
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in hypertension (HTN) comparing addition of spironolactone with Placebo (2 arms). Primary endpoints: Change of Systolic Blood Pressure at 4 months and Change of Diastolic Blood Pressure at 4 months. Started Mar 2010; status: completed.
02
Drugs
spironolactone
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT01062763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01062763.